Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

What Was Tested

This randomized controlled trial paper looks at Glucagon.

The aim of this study was to assess the effect of an eight hour infusion of GLP-1 on appetite and energy intake at lunch and dinner in obese subjects.

Who Took Part

By PubMed's age tags, the people studied were adults, men only.

Eight obese (body mass index, BMI, 45.5 +/- 2.3 kg/m2) male subjects.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

Ad libitum energy intake at lunch (12.00 h) and dinner (16.00 h) after an energy fixed breakfast (2.4 MJ) at 08.00 h.

Appetite sensations using visual analogue scales, (VAS) immediately before and after meals and hourly in-between.

Blood samples for the analysis of glucose, insulin, C-peptide, GLP-1 and peptide YY.

Gastric emptying after breakfast and lunch using a paracetamol absorption technique.

What Was Measured

Topics PubMed links to this paper include Appetite, Blood Glucose, Body Mass Index, C-Peptide, Eating, Energy Intake and Gastric Emptying.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Glucagon.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1999 (International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity), a journal based in England.

More context: the Glucagon compound page, all human trials.